Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus - A prospective cohort study.

CONCLUSION: CMR evidence of subclinical LM persisted despite improved SLEDAI-2K, serological markers, cardiac function and CMR mass index. Subclinical LM did not progress to clinical LM and had no significant prognostic implications over 12 months. Immunosuppressive therapy did not have any significant effect on the presence of CMR evidence of myocardial tissue injury. Improvement in CMR mass index correlated with reduction in myocardial oedema and may be used to monitor SLE myocardial injury.
PMID: 33525979 [PubMed - in process]

Source: Lupus - February 1, 2021 Category: Rheumatology Authors: du Toit R, Herbst PG, Ackerman C, Pecoraro AJ, Claassen D, Cyster HP, Reuter H, Doubell AF Tags: Lupus Source Type: research